Larimar Therapeutics
LRMR
69 hedge funds and large institutions have $180M invested in Larimar Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 3 closing their positions.
355% more call options, than puts
Call options by funds: $378K | Put options by funds: $83K
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
17% more capital invested
Capital invested by funds: $153M → $180M (+$26.5M)
6% more funds holding
Funds holding: 65 → 69 (+4)
0.33% more ownership
Funds ownership: 89.52% → 89.86% (+0.33%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$11.5M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$919K |
| 3 |
Janus Henderson Group
London,
|
+$606K |
| 4 |
BlackRock
New York
|
+$537K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$759K |
| 3 |
Walleye Capital
New York
|
-$500K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$302K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$270K |
LRMR Hedge Fund Activity: Q4 2023 in Review
69 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2023, worth a combined $180M — up 17% from $153M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LRMR positions and 3 closed out — a net gain of 5 holders — while 23 added to existing stakes and 25 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $11.5M. The largest seller was Citadel Advisors, cutting an estimated $1M.
- 69 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2023, up from 65 in Q3 2023.
- Funds reported $180M of Larimar Therapeutics stock for Q4 2023, up 17% quarter-over-quarter.
- 8 funds opened new Larimar Therapeutics positions in Q4 2023 and 3 closed out, a net change of +5 holders.
- The largest Larimar Therapeutics buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $11.5M added.
- The largest Larimar Therapeutics seller in Q4 2023 was Citadel Advisors, an estimated $1M sold.
Based on aggregated 13F filings for Q4 2023.